Pavel Kapysh / Shutterstock.com
Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza (metformin hcl).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
monopoly, antitrust, diabetes, settlement, class-action